vancomycin has been researched along with Macular Degeneration in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caramoy, A; Fauser, S; Kirchhof, B; Lappas, A; Schroeder, S | 1 |
| Brown, GC; Garg, SJ; Haller, JA; Kaiser, RS; Shah, CP; Vander, JF | 1 |
2 other study(ies) available for vancomycin and Macular Degeneration
| Article | Year |
|---|---|
Intraocular inflammation after intravitreal ranibizumab injections.
Topics: Aged; Angiogenesis Inhibitors; Anterior Chamber; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ceftazidime; Drug Therapy, Combination; Endophthalmitis; Female; Glucocorticoids; Humans; Intravitreal Injections; Macular Degeneration; Ranibizumab; Retreatment; Vancomycin; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2011 |
Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aqueous Humor; Bevacizumab; Case-Control Studies; Ceftazidime; Endophthalmitis; Eye Infections, Bacterial; Female; Humans; Intravitreal Injections; Macular Degeneration; Male; Ranibizumab; Retrospective Studies; Risk Factors; Tobramycin; Treatment Outcome; Vancomycin; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2011 |